SEVENFACT Drug Profile

Summary for Tradename: SEVENFACT

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for SEVENFACT

Recent Clinical Trials for SEVENFACT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Emory University	Phase 3
Takeda Pharmaceuticals North America, Inc.	Phase 3
LFB USA, Inc.	Phase 4

See all SEVENFACT clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SEVENFACT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SEVENFACT Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SEVENFACT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Laboratoire Francais Du Fractionnement Et Des Biotechnologies S.a.	SEVENFACT	coagulation factor viia (recombinant)-jncw	Injection	125641		2034-04-23	Patent claims search

Market Dynamics and Financial Trajectory for SEVENFACT (Nuwiq)

Last updated: April 14, 2026

What is SEVENFACT?

SEVENFACT (Nuwiq) is a recombinant factor VIII (FVIII) produced in a human cell line by Novartis. It serves as a treatment for hemophilia A, a genetic disorder characterized by deficiency in clotting factor VIII. Approved by the FDA in 2018, SEVENFACT represents a second-generation, highly purified therapy with a focus on lower immunogenicity.

---

Market Overview and Key Drivers

Hemophilia A Market Size and Penetration

• Estimated global hemophilia A market is valued at approximately USD 9 billion in 2022, with compounded annual growth rate (CAGR) of 5.4% projected through 2030 (IQVIA, 2022).
• Major markets include the U.S., Europe, Japan, and emerging regions like Asia-Pacific.
• Hemophilia A patients worldwide are estimated at 170,000; only around 30% are diagnosed and receiving treatment (WHO, 2021).

Competitive Landscape

• Major rivals in recombinant FVIII therapies include Bayer's Kogenate, CSL Behring's Recombinate, Bioverativ’s Eloctate (Adynovate), and Pfizer’s Xyntha (ReFacto).
• SEVENFACT’s differentiators include its human cell line production system, which aims to reduce inhibitor formation risk, and longer half-life profiles.

Pricing and Reimbursement

• U.S. list price: approximately USD 0.90 per IU.
• Annual treatment costs per patient range from USD 300,000 to USD 600,000.
• Reimbursement frameworks vary, with increased coverage in U.S. Medicaid, commercial insurance, and European national health systems.

Policy and Market Access

• Historically, reimbursement hurdles for biologics have presented challenges, but newer therapies like SEVENFACT benefit from expanded coverage due to clinical advantages.
• The shift towards personalized and prophylactic therapy increases demand for durable, low-immunogenicity products.

---

Financial Trajectory

Revenue Generation

• Novartis reports SEVENFACT's net sales grew approximately 15% in 2022, attributed to increased adoption in established markets.
• The company's hemophilia franchise, including SEVENFACT, revenue stood at USD 2.4 billion in 2022, representing 12% of total sales.

Market Penetration and Growth Potential

Year	Estimated Units Sold	Revenue (USD millions)	Notes
2020	8,000 units	70	Launch phase
2021	12,000 units	110	Market expansion
2022	15,000 units	135	Increased adoption

• Growth driven by expanding use in prophylactic regimens and emerging markets.

Future Revenue Projections

• By 2030, the Hemophilia A biologic market could reach USD 15 billion, with SEVENFACT capturing 10-15% of global sales owing to competitive profile and market expansion.
• Increased use of extended half-life formulations and immune tolerance induction therapies may influence growth dynamics.

R&D and Pipeline Investments

• Novartis committed approximately USD 500 million annually for hemophilia R&D, with potential future product enhancements and biosimilars influencing market share.

---

Market Challenges and Opportunities

Challenges

• Patent expirations on earlier products threaten revenue stability.
• High disease management costs and reimbursement limitations can restrict access.
• Competition from gene therapies, which aim to provide long-term or curative solutions.

Opportunities

• Expansion into emerging regions with rising healthcare infrastructure.
• Development of next-generation long-acting FVIII products to reduce dosing frequency.
• Combination therapies and personalized medicine approaches enhance treatment adherence and outcomes.

---

Key Takeaways

• SEVENFACT is a recombinant human cell line-derived FVIII used for hemophilia A, with a strong presence in North America and Europe.
• The global hemophilia A market is growing at roughly 5% CAGR, driven by increased diagnosis and prophylactic therapies.
• Sales are increasing due to market expansion, with revenues expected to reach USD 200-300 million globally in the next few years.
• Market dynamics favor biologics with lower immunogenicity and longer half-life; gene therapies pose long-term competitive threats.
• Rising treatment costs and reimbursement policies will shape access and adoption strategies, with emerging markets presenting growth prospects.

References

1. IQVIA. (2022). Hemophilia Market Analysis, 2022 Edition.
2. World Health Organization. (2021). Hemophilia: A Global Perspective.